Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 14/20 | 0.71 |
| ▸ | CASP7 | P55210 | 10/20 | 0.71 |
| ▸ | CASP1 | P29466 | 6/20 | 0.71 |
| ▸ | CASP9 | P55211 | 5/20 | 0.71 |
| ▸ | CASP4 | P49662 | 3/20 | 0.59 |
| ▸ | CASP10 | Q92851 | 3/20 | 0.59 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.59 |
| ▸ | CASP5 | P51878 | 1/20 | 0.59 |
| ▸ | CASP6 | P55212 | 1/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.54 |
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29732392 | 1.00 | CASP3 (0.71) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL28540771 | 0.97 | CASP3 (0.68) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL17326941 | 0.93 | CASP3 (0.72) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL29362585 | 0.92 | CASP3 (0.76) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL29004082 | 0.92 | CTSL (0.59) | CASP3CASP7CASP1CASP9CTSL | |
| SCHEMBL28399571 | 0.92 | CASP3 (0.70) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL30002726 | 0.89 | CASP3 (0.69) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL16770334 | 0.88 | CASP3 (0.68) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2744395 | 0.88 | CASP3 (0.68) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL6657994 | 0.88 | CASP3 (0.78) | CASP3CASP7CASP1CASP9CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551034-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | Progenity, Inc. (US) | 2019-10-16 | — | — | EP | claimed |
| WO-2018106933-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | PROGENITY INC. (US) | 2018-06-14 | — | — | WO | claimed |
| EP-3802850-B1 | DEVICES AND SYSTEMS FOR GASTROINTESTINAL MICROBIOME DETECTION AND MANIPULATION | BT BIDCO INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250082265-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOSUPPRESSANT | BT BIDCO, INC. | 2025-03-13 | — | — | US | disclosed |
| US-20250000364-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | GLAS USA LLC | 2025-01-02 | — | — | US | disclosed |
| US-12150775-B2 | Treatment of a disease of the gastrointestinal tract with an immunosuppressant | BIORA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240335644-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNE MODULATORY AGENT RELEASED USING AN INGESTIBLE DEVICE | GLAS USA LLC | 2024-10-10 | — | — | US | disclosed |
| US-12089916-B2 | Gastrointestinal tract detection methods, devices and systems | BIORA THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| EP-4410832-A2 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | Biora Therapeutics, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| US-11857669-B2 | Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices | BIORA THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230309917-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOSUPPRESSANT | GLAS USA LLC | 2023-10-05 | — | — | US | disclosed |
| WO-2018112264-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHEMOKINE/CHEMOKINE RECEPTOR INHIBITOR | PROGENITY INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112240-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TNF INHIBITOR | PROGENITY INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112232-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IL-12/IL-23 INHIBITOR RELEASED USING AN INGESTIBLE DEVICE | PROGENITY INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112256-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IL-1 INHIBITOR | PROGENITY INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018106959-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | PROGENITY INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106931-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | PROGENITY INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106933-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | PROGENITY INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106945-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | PROGENITY INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180164221-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | BT BIDCO LLC | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12089916-B2 | Gastrointestinal tract detection methods, devices and systems | FABP2, SI, MLNR | CASP3 3662/4885CASP7 4244/4885CASP1 3679/4885 |
| US-20230309917-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOSUPPRESSANT | TPMT, FABP2, SLC10A2 | CASP3 1812/4885CASP7 2900/4885CASP1 2044/4885 |
| US-11857669-B2 | Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices | JAK1, JAK3, JAK2 | CASP3 3350/4885CASP7 3811/4885CASP1 2579/4885 |
| US-20250082265-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNOSUPPRESSANT | TPMT, FABP2, SLC10A2 | CASP3 1812/4885CASP7 2900/4885CASP1 2044/4885 |
| US-20240335644-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNE MODULATORY AGENT RELEASED USING AN INGESTIBLE DEVICE | CD40LG, CD40, ICOS | CASP3 3851/4885CASP7 4193/4885CASP1 2634/4885 |
| US-20250000364-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | FABP2, SI, MLNR | CASP3 3662/4885CASP7 4244/4885CASP1 3679/4885 |
| US-12150775-B2 | Treatment of a disease of the gastrointestinal tract with an immunosuppressant | TPMT, FABP2, SLC10A2 | CASP3 1812/4885CASP7 2900/4885CASP1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.